We encourage you to keep abreast and updated on our activities at AKESOgen, published here regularly.

athena

AKESOgen to Analyze Specimens in Breast Cancer Research

Edith Sanford Breast Cancer, Athena Breast Health Network Team for Breast Cancer Research; Akesogen to Perform Analysis

Genetic analysis of 3,000 women could identify cancer risk
 

Newswise – (Sioux Falls, SD/San Francisco, CA) – Three-thousand bio specimens from women will be analyzed as part of the ongoing collaboration between Edith Sanford Breast Cancer and Athena Breast Health Network to determine whether certain genetic variants could be indicators of breast cancer, officials from both organizations announced today.

The effort aims to gather information that will impact prevention strategies and more precisely identify risk levels of developing breast cancer.

As part of the study, 1,500 women at elevated risk and 1,500 women at average risk for breast cancer will be genotyped.

“We believe this to be one of the largest groups of women to ever be studied to determine breast cancer risk levels,” said Gene Hoyme, MD, president of Sanford Research. “If an elevated risk is identified, care teams can improve the likelihood of healthier lifestyle changes and implement preventative treatments when appropriate.”

In November, Edith Sanford Breast Cancer and Athena Breast Health Network announced a partnership in which Sanford Health became a clinical partner with the Athena Breast Health Network, positioning the health system to begin providing patients with a comprehensive breast cancer risk assessment at the time of mammography screening. Additionally, the program will offer patients the opportunity to participate in research aimed at gaining a better understanding of breast cancer and its risk factors, ultimately raising the standard of care for women everywhere.

To analyze each sample from the 3,000 women, AKESOgen, an Atlanta-based biomarker and genetics company selected by Edith Sanford and Athena, will utilize Oncochip technology.

“The Oncochip is a uniquely designed genetic analysis tool that uses Illumina’s beadarray technology. It will allow us to provide genetic data of the highest quality to the collaboration. The data will benefit both the participants and the breast cancer research community,” said Mark Bouzyk, PhD, chief scientific officer of AKESOgen.

Data gathered and studied by Edith Sanford and Athena could positively influence the risk-assessment tool and care plans.

“The addition of the genetic variants risk assessment allows us to deliver a new level of personalized medicine and gain a better understanding an individual’s risk, thus putting our collaboration at the forefront of modern medicine,” said Laura van `t Veer, PhD, Director of Applied Genomics at the University of California, San Francisco and an Athena spokesperson.

Athena Breast Health Network is a collaboration among the five University of California medical centers. Edith Sanford Breast Cancer is its first partner outside of California and was selected because of its expertise in breast cancer genomics and its ability to integrate the risk assessment into patient care.

About Sanford Health and Edith Sanford Breast Cancer Sanford Health is the largest rural nonprofit health care system in the nation with locations in 126 communities, in nine states. In addition, this dynamic integrated health system is now developing international clinics in Ghana, Israel and Mexico. Sanford Health has more than 26,000 employees, and includes 39 hospitals, 140 clinic locations and 1,360 physicians in 81 specialty areas of medicine. In 2011, Sanford Health announced the launch of the Edith Sanford Breast Cancer Initiative, a bold new endeavor to end breast cancer, comprised of state-of-the-art patient care, genomic research and national fundraising through the Edith Sanford Breast Cancer Foundation. For more information, visit sanfordhealth.org or edithsanford.org.

About Athena Breast Care Network The Athena Breast Health Network (Athena) is a unique collaboration among the five University of California (UC) medical/cancer centers (UC Davis, UC Irvine, UCLA, UC San Diego and UCSF), the Graduate School of Public Health at UC Berkeley, and many other public and private partners. The Network takes a transdisciplinary approach by design, and its participants work together across fields including: epidemiology, genetics, molecular biology, psychology and social and behavioral sciences, primary care, radiology, pathology, oncology, surgery and health services research. Also included are clinical staff and genetic counselors, health information technology professionals, health care administrators, and importantly, patient advocates.

Athena is integrating clinical care and research in order to revolutionize the delivery of breast care. By standardizing the collection of data from both patients and physicians, integrating molecular profiling at the time of breast cancer diagnosis, and creating an unparalleled biospecimen repository, Athena will enable personalized care informed by science and will fuel continuous improvement in treatment options and outcomes.

Key components of Athena include:

  • Identifying women at high risk for breast cancer who will be offered prevention services and decision support.
  • A comprehensive informatics strategy that includes tools to collect, analyze, and distribute clinical and research data in real time.
  • Web-based decision tools for patients and providers to translate clinical evidence into actionable treatment options – allowing physicians to tailor treatment to biology, patient preference and clinical performance.
  • A data and biospecimen repository to support large-scale, longitudinal studies that will enable tailored prevention and treatment strategies.

 

Underpinning these goals is a culture that supports continuous improvement, as well as a commitment by Athena clinicians and researchers across California to share data. With this unique collaboration, Athena aims to change the options for patients today and create a better future for all women at risk of developing breast cancer.

UC Disclaimer The information stated above was prepared by Sanford Health and reflects solely the opinion of the health system. Nothing in this statement shall be construed to imply any support or endorsement of Sanford, or any of its products, by The Regents of the University of California, its officers, agents and employees.

About AKESOgen, Inc. AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com.

– See more at: http://www.akesogen.com/?page=pr-2014-03-04#sthash.PKLo4gfY.dpuf

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
gwinn

AKESOgen, Expands Footprint in Gwinnett County, Metro Atlanta


Life Science Startup, AKESOgen, Expands Footprint in Gwinnett County, Metro Atlanta
Company triples space, plans for future growth
 

(GWINNETT- METRO ATLANTA) December 18, 2013 – Genomics and biorepository services company, AKESOgen, Inc., joined Gwinnett Chamber Economic Development and the Georgia Department of Economic Development to announce its expansion and new location in Gwinnett County, metro Atlanta, Georgia. AKESOgen will more than triple its square footage with of its move to a 13,727-square-foot facility, located at 3155 Northwoods Place in the City of Peachtree Corners. The company expects to add up to an additional ten employees in 2014.

“Since our inception just over three years ago, we have been impressed with the resources, support, and growth opportunities available to biotech companies in Gwinnett County, metro Atlanta and Georgia,” stated Dr. Mark Bouzyk, Chief Scientific Officer for AKESOgen, Inc. “This larger facility will both strengthen our ability to deliver genomics research and development, as well as complement our existing competence in the biotech field.”

Earlier this year, AKESOgen joined the Georgia Department of Economic Development, Innovation Crescent, and six additional life science companies to promote Georgia as a life science hub at the 2013 BIO International Convention, held in Chicago.

“Innovative life science companies such as AKESOgen are what make our state the healthcare hub of the Southeast,” said Carol Henderson, director of life sciences and technology at the Georgia Department of Economic Development. “AKESOgen will lay the foundation for tomorrow’s life science discovery, and we are confident that Georgia’s pro-business climate can support the company in doing so.”

Gwinnett County and AKESOgen are located in the heart of Georgia’s Innovation Crescent, a geographical region and collaborative partnership of more than 15 counties and economic development entities all dedicated to supporting the state’s life science and technology growth. Anchored by Atlanta’s Hartsfield-Jackson International Airport on one end and the University of Georgia in Athens-Clarke County on the other, the Innovation Crescent encompasses a wide range of companies and institutions committed to furthering life science research. AKESOgen represents one of these companies and will be surrounded by the resources of top research organizations in the Southeast.

“Our goal as a region is to broaden and enhance life science and technology in the region and an expansion such as this one demonstrates the success of those efforts,” commented Nick Masino, Chair of Georgia’s Innovation Crescent and Senior Vice President of Gwinnett Chamber Economic Development and Partnership Gwinnett. “As a member of the Innovation Crescent Regional Partnership, Gwinnett Chamber Economic Development actively works to promote, support and encourage the growth of companies in these industries.”

Gwinnett County Board of Commission Chairman Charlotte Nash, stated, “This expansion supports Gwinnett’s reputation as a hub for research, development and innovation in the Southeast. AKESOgen remains an important contributor to our life sciences community and we are grateful for its decision to remain and grow in Gwinnett.”

According to data released by the Bureau of Labor and Statistics, nearly 30 life science and biotechnology companies call Gwinnett home. AKESOgen represents the third Gwinnett company involved in one of these industries to expand in the past six months alone.

“We welcome AKESOgen, and view its investment in the City of Peachtree Corners and Gwinnett as a testament to our community’s strength in this developing, vibrant and progressive industry,” said City of Peachtree Corners Mayor Mike Mason.

AKESOgen provides biomarker profiling and genomics services for the research and development market, including biobanking, DNA/RNA extraction, and genetic technologies. Founded in 2010, the company serves the clinical, pharmaceutical, biotechnology, academic and government sectors.

To learn more about AKESOgen, please visit www.akesogen.com.

For more information, or to learn how to get involved in local economic development efforts, please visit www.gwinnetteconomicdevelopment.com.

About AKESOgen, Inc.
AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the R&D market in to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and agricultural sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility.

About Gwinnett Chamber Economic Development
Gwinnett Chamber Economic Development globally markets Gwinnett as the premier location in metro Atlanta and the State of Georgia for growing and conducting business. By encouraging investment and trade into the county through relocation and expansion assistance, the organization works with local and regional partners to bring technology, health sciences and services, advanced manufacturing, supply chain management, and corporate headquarters to the community. Home to FORTUNE 500 and 1000 companies, Gwinnett County hosts a wide range of businesses from industry giants, to international companies and homegrown start-ups. Success lives here- www.gwinnetteconomicdevelopment.com.

Media Contact

Dr. Mark Bouzyk | mbouzyk@akesogen.com | 404.771.8667
Sasha Ugi | Sasha@gwinnettchamber.org | 678.584.2261

– See more at: http://www.akesogen.com/?page=pr-2013-12-18#sthash.qrWs5s9h.dpuf

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
id

AKESOgen and Identitas Partner

 

 

AKESOgen and Identitas partner to provide a comprehensive Next Generation Forensic profiling solution

 

New York, NY, USA and Norcross, GA, USA – August 16th 2013 – Identitas Corp., a leader in forensic phenotyping and AKESOgen, the genomics and biorepository services company today announced a global commercial partnership to offer the forensic industry an innovative turn-key phenotypic screening solution that allows investigators to generate more comprehensive leads from DNA samples than had previously been possible. Financial terms were not disclosed.

“Our unique technology creates highly specific phenotypic predictions from DNA, combining inferences on biogeographic ancestry, extended relatedness/kinship, gender, Y and mitochondrial haplotype, and physical appearance such as hair and eye color. ISAS™ is able to generate investigative leads rapidly using only a single aliquot of DNA. We evaluate genome-wide single nucleotide polymorphisms (SNPs), to extract greater insight from DNA samples than has previously been possible” said Dr. Aruna Bansal, CIO of Identitas.

“We are excited to be working with Identitas to provide a comprehensive solution which we believe is unique in the forensic market and will have tremendous utility for enhanced phenotyping of individuals for a variety of applications including missing person identification as well as investigative lead generation, to complement standard panels such as CODIS.” commented Dr. Mark Bouzyk, CSO of AKESOgen.

The partnership will harness the combined strengths of both companies: AKESOgen will provide an end-to-end genetic analysis package powered by Identitas’s proprietary ISAS™ software analysis tool. ISAS™ employs a computationally powerful approach that interrogates single nucleotide polymorphisms (SNPs) to develop a profile that describes the physical appearance of an individual. AKESOgen has entered in to a license agreement with Identitas for access to the ISAS™ software, enabling customers a seamless delivery of an enhanced phenotypic profile from receipt of DNA.

–ENDS–
Notes to Editors:

Contact details

Mark Bouzyk, PhD, Chief Scientific Officer, AKESOgen, Inc.
T: +1 855 661 8920 (Toll Free)
C: +1 404 771 8667
E: mbouzyk@akesogen.com

Aruna Bansal MSc, PhD, CStat, CSci, Chief Information Officer, Identitas Corp.
C: +44 1223 421 662
E: bansal@identitascorp.com

About AKESOgen, Inc.

AKESOgen is an integrated genomics and company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the R&D market in a CLIA environment. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the government, academic, pharmaceutical, biotechnology, clinical testing and agricultural sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com

About Identitas Corp.

Identitas Corp. is a forensic genomics company developing better ways to extract information from genetic evidence. Their lead software product, ISAS™, is an all-in-one solution that generates highly detailed profiles from a single DNA sample. ISAS™ provides simple, intuitive reports of high resolution data that describe familial relatedness, bio-geographic ancestry/location of origin, and visual phenotyping. For more information, visit www.identitascorp.com

– See more at: http://www.akesogen.com/?page=pr-2013-08-16#sthash.DZmANyjv.dpuf

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
london

AKESOgen and London Genetics International alliance to enhance drug development

 

 

AKESOgen and London Genetics International alliance to enhance drug development through pharmacogenetics and related services

Norcross, GA, US and London, UK – March 29th 2012 – AKESOgen, the genomics and biorepository services company, and London Genetics International, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine and provide trans Atlantic services. The alliance combines world-class expertise and American-European infrastructure to support biopharma drug development. Financial terms were not disclosed.

“Our expertise in pharmacogenetic strategy development combined with a professional genomics services company that operates to CLIA standards will make this strategic alliance beneficial to both companies as it will increase our scope of possible services into the Americas with highly qualified and service oriented scientists. This represents our first deal following our acquisition by LSBC which from our side was a critical step for making this happen” said Elizabeth Foot, VP Personalised Medicine and Nutrition, London Genetics International.

Under the alliance, AKESOgen and London Genetics International will collaborate to help biopharma companies take advantage of pharmacogenetic solutions, including novel biomarker and assay development services. By providing biopharma companies strategic advice on the application of pharmacogenetics and innovative pharmacogenetics solutions, AKESOgen and London Genetics can help customers access additional resources and speed the delivery of targeted treatments.

Notes to Editors:

Contact details

Mark Bouzyk, PhD, Chief Scientific Officer, AKESOgen, Inc.
T: +1 855 661 8920 (Toll Free)
C: +1 404 771 8667
E: mbouzyk@akesogen.com

Elizabeth Foot, DPhil, London Genetics International
C: +44 (0) 7540 722236
E: efoot@londongenetics.com

About AKESOgen, Inc.

AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the R&D market in to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and agricultural sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility.

www.akesogen.com

About London Genetics International

London Genetics International has extensive experience and expertise in the fields of personalized medicine and nutrition. The Company provides strategic advice on the application of these approaches to optimize clinical development and commercialization of stratified medicines, as well as for the development of novel food products and stratified nutritional strategies. London Genetics fosters open innovation approaches and has established relationships with major academic sites within London, Central Europe and the USA. It works at the academic-industry interface to facilitate partnerships between industry and academic centers of excellence. These centers are at the forefront of research in genetics, translation medicine and nutrition with access to large patient cohorts and samples across a breadth of therapeutic areas, as well as cutting edge technologies.

London Genetics International Ltd is the trading name for LSBC (London) Ltd.

www.londongeneticslimited.com

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
ba

AKESOgen a Winner of British Airways “Face of Opportunity” Competition for Small Businesses

AKESOgen SELECTED AS 2010 BRITISH AIRWAYS FACE-OF-OPPORTUNITY WINNER
 

New York, Dec. 1st, 2010 – AKESOgen, today announced that it has been selected by British Airways as a 2010 Face-of-Opportunity winner and has been awarded travel to anywhere in the world to conduct vital business meetings as well as attend the British Airways Face-of-Opportunity business conference. This award is part of the British Airways Face-to-Face program, which provides small business owners and entrepreneurs the critical tools for building business relationships abroad and stimulating growth through the power of face- to-face interaction.

“We are thrilled to be part of the prestigious group of entrepreneurs that were chosen by British Airways as a Face-of-Opportunity winner,” said AKESOgen CEO Bob Boisjoli. “This flight will give us the chance to meet our key customers in 2011, which is vital for the growth of our business in 2011.”

Before taking off, AKESOgen will attend the British Airways Face-of-Opportunity conference in New York City on Feb. 2, 2011 where the company will receive free counsel from top influential international business experts while networking with venture capitalists, renowned entrepreneurs, media and other small business owners.

The conference, which includes an introduction by Simon Talling-Smith, Executive Vice President Americas, British Airways, and keynote speeches by Rhonda Abrams, best-selling author and USA Today small business columnist and Bill Rancic, best-selling author and first season winner of The Apprentice, will provide AKESOgen with additional tools in business planning, marketing and travel to assist the company in its strategy to enhance its mission in personalized medicine.

“We are very excited for this phase of the program and for the winning small business owners who, beyond the educational resources already provided through the Face-to-Face program, now have the opportunity to fly British Airways overseas to conduct vital face-to-face meetings for their business,” said Simon Talling-Smith. “Each of the winner’s stories is uniquely inspiring and our hope is that the program is a powerful catalyst in ensuring lasting and fruitful businesses for them.”

About AKESOgen:
AKESOgen is a genomics Contract Research Organization that provides genomics and pharmacogenomics services to the academic, pharmaceutical, biotech and agricultural sectors.

About British Airways:
British Airways is one of the world’s largest international airlines. Operating one of the most extensive international scheduled airline route networks, together with its codeshare and franchise partners, the airline flies to more than 300 destinations worldwide. Also, one of the world’s longest established airlines, it has always been regarded as an industry-leader. British Airways flies its customers at convenient times to the best located airports across the world.

British Airways is one of the world’s leading global premium airlines with its principal place of business in London with significant presence at Heathrow, Gatwick and London City. It also operates a worldwide air cargo business, largely in conjunction with scheduled passenger services. The airline operates the majority of its domestic UK, international and intercontinental flights from its home at Terminal 5, Heathrow.

Whether customers are in the air or on the ground, British Airways takes pride in providing a full service experience.

Additional information on Face-to-Face is available by visiting the airlines website, ba.com/facetoface.
CONTACT:
Jacquelyn Einaugler for British Airways
Text 100 Public Relations
Email: jacquelyn.einaugler@text100.com
Phone: 212.871.3952

– See more at: http://www.akesogen.com/?page=pr-2010-12-01#sthash.Ini8Z02b.dpuf

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail